US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
1.460
-0.040 (-2.67%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
September 02, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in September Investor Conference
August 31, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene (ALLO) Q2 2026 Earnings Call Transcript
↗
August 19, 2026
Cema-cel hit 58.3% MRD negativity in ALPHA3 with zero treatment hospitalizations.
Via
The Motley Fool
Topics
Earnings
Allogene Therapeutics Q2 Earnings Call Highlights
↗
August 12, 2026
Allogene Therapeutics (NASDAQ:ALLO) outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3...
Via
MarketBeat
Topics
Earnings
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 04, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
July 15, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Planned CEO Succession
May 28, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 26, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Q1 Earnings Call Highlights
↗
May 13, 2026
Allogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April...
Via
MarketBeat
Topics
Earnings
Allogene (ALLO) Q1 2026 Earnings Transcript
↗
May 13, 2026
Allogene (ALLO) Q1 2026 Earnings Transcript
Via
The Motley Fool
Allogene Therapeutics Q1 2026 Earnings Call Transcript
↗
May 13, 2026
Via
Benzinga
Topics
Earnings
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
May 13, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 06, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
April 21, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
April 20, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
April 16, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Thursday's session: gap up and gap down stocks
↗
April 16, 2026
Via
Chartmill
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
April 15, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
April 14, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
April 14, 2026
US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading.
Via
Benzinga
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
April 13, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
These stocks are making the most noise in today's session.
↗
April 13, 2026
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via
Chartmill
ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology
April 13, 2026
Via
AB Newswire
Allogene Therapeutics Stock Hits 52-Week High - Here's Why
↗
April 13, 2026
Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.
Via
Benzinga
These stocks are gapping in today's session
↗
April 13, 2026
Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday
↗
April 13, 2026
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.
Via
Benzinga
Topics
Stocks
Which stocks are moving before the opening bell on Monday?
↗
April 13, 2026
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
April 13, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
